20/20 BioLabs Hosts Webinar on FDA Advisory Committee Vote and OneTest™ Franchise Model

GAITHERSBURG, Md., Sept. 29, 2026 /CourierPR/ -- 20/20 BioLabs, Inc., a company developing AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, is set to host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern Time.

President and CEO Jonathan Cohen will lead the discussion, covering several critical topics. He will delve into the September 23, 2026, meeting of the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee, where the panel voted favorably regarding the safety, effectiveness, and overall benefit-risk profile of GRAIL’s Galleri® multi-cancer early detection (MCED) blood test for screening adults aged 50 years and older. Cohen will explore what this vote might indicate for the broader MCED category.

Additionally, Cohen will discuss the regulatory and reimbursement strategy 20/20 BioLabs is pursuing for its OneTest™ for Cancer, including the statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028. The company’s goal is to achieve Medicare reimbursement for MCED by the end of 2028.

Another significant topic of discussion will be the company’s newly introduced OneTest™ franchise model. Under this model, independent regional laboratories will offer OneTest™ within defined territories and verticals, while 20/20 BioLabs retains ownership of its machine-learning models, patented methods, and longitudinal biomarker data. Cohen will explain how this model could support broader commercial expansion without the need to build a national sales force.

The webinar will also touch on preliminary interest the company has received from laboratories across the United States. Cohen will discuss how this interest could contribute to the company’s growth strategy.

Lastly, the event will feature a live question-and-answer session with management, providing investors and other interested parties with the opportunity to engage directly with the company’s leadership.

Registration for the webinar is now open, and attendees will receive a promotional discount code for OneTest™ at the conclusion of the event. The offer will be available to all attendees, regardless of shareholder status.